Press Releases


Press Releases

Date Title and Summary
Toggle Summary Finacea(R) (azelaic acid) Foam 15%, Approved by U.S. FDA for Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea
REHOVOT, Israel and RALEIGH, N.C. , July 31, 2015 (GLOBE NEWSWIRE) -- As announced today by Bayer HealthCare , the U.S. Food & Drug Administration ( FDA ) has approved Finacea® (azelaic acid) Foam, 15% for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
Toggle Summary Foamix Announces $16 Million Investment by OrbiMed
REHOVOT, Israel and BRIDGEWATER, N.J. , April 16, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Appointment of Dr. Aaron Schwartz to Board of Directors
REHOVOT, Israel , and BRIDGEWATER, N.J. , May 7, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX) ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Closing of its Follow-on Offering of Ordinary Shares and Full Exercise of its Option by the Underwriters
REHOVOT, Israel , and BRIDGEWATER, N.J. , Sept. 18, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea
REHOVOT, Israel and BRIDGEWATER, N.J. , May 03, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX101
Expected to Report Top-Line Results on Schedule in First Half of 2017 REHOVOT, Israel , and BRIDGEWATER, New Jersey , Nov. 28, 2016 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing and
Toggle Summary Foamix Announces Dosing of First Patient in Phase 3 Acne Studies for Minocycline Foam FMX101
REHOVOT, Israel , and BRIDGEWATER, N.J. , May 09, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that the
Toggle Summary Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5%
REHOVOT, Israel and BRIDGEWATER, New Jersey , June 12, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that
Toggle Summary Foamix Announces Dosing of First Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101
Company validates clinical development pathway via FDA Type B Meeting REHOVOT, Israel , and BRIDGEWATER, New Jersey , Aug. 3, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary
Toggle Summary Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103
Top-line results expected early Q4 2018 Rehovot, Israel, and Bridgewater, NJ – June 27, 2018  – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology,